Sign in

You're signed outSign in or to get full access.

Reuven Yeganeh

Director at Nukkleus Inc.
Board

About Reuven Yeganeh

Independent director since June 13, 2024; age 48 as of the 2025 proxy. Background in fund management and derivatives trading with prior chair roles at TASE-listed companies; BA in Economics & Administration (Ruppin College, 2004) and Israeli Securities Authority portfolio manager license (2006). Designated Audit Committee Financial Expert and Chair of the Audit Committee; also serves on Compensation and Nominating & Corporate Governance committees. The Board determined he is independent under Nasdaq rules and Exchange Act Rule 10A-3 .

Past Roles

OrganizationRoleTenureCommittees/Impact
Inbar Group Finance Ltd.Derivatives Trader2021–present Financial markets expertise; risk management
Fantazy Network (TASE: WILK)Chairman of the Board2018–2021 Cannabis investments; board leadership
Direct Capital (TASE: DCI-M)Chairman of the Board2012–2018 Real estate investments; governance oversight
Israeli Air ForceNon-Commissioned Officer1998–2001 Discipline and operational leadership

External Roles

OrganizationMarketRoleTenureNotes
Fantazy NetworkTASEChairman2018–2021 Cannabis sector board chair
Direct CapitalTASEChairman2012–2018 Real estate investment board chair

Board Governance

  • Independence: Board determined Yeganeh is independent under Nasdaq rules and Rule 10A-3; no family relationships disclosed among directors and officers .
  • Committee roles: Audit Committee Chair and Audit Committee Financial Expert; member of Compensation and Nominating & Corporate Governance Committees .
  • Committee meeting frequency (FY 2024/three months ended Dec 31, 2024): Audit met three times; Compensation met once; Nominating & Corporate Governance met once .
  • Annual Meeting attendance policy: Directors encouraged to attend; Board actions often by written resolutions; no specific individual attendance rates disclosed .
Governance ElementDetail
Audit CommitteeChair; Financial Expert; met 3 times in year ended 2024
Compensation CommitteeMember; Chair is Aviya Volodarsky; met 1 time in FY ended Dec 31, 2024
Nominating & Corporate GovernanceMember; Chair is David Rokach; met 1 time in FY ended Dec 31, 2024

Director election support (Nov 6, 2025):

NomineeFORWITHHELDBroker Non-Vote
Reuven Yeganeh5,041,088 94,809 0

Fixed Compensation

PeriodFees Earned or Paid in Cash ($)All Other Compensation ($)Total ($)
FY ended Sep 30, 20245,833 5,833
Three months ended Dec 31, 20245,000 5,000

Performance Compensation

PeriodStock Awards ($)Option Awards ($)Non-Equity Incentive Plan Compensation ($)
FY ended Sep 30, 2024
Three months ended Dec 31, 202413,900

Performance metrics tied to director pay:

Metric CategoryTarget/DefinitionDisclosed?
Revenue/EBITDA/TSR-based director incentivesNot typical for non-employee directorsNone disclosed
Meeting fees/performance bonusesNot disclosedNone disclosed
Equity award vesting schedules (RSUs/DSUs)Not detailed for directorsNot disclosed

Other Directorships & Interlocks

  • Interlocks: Board includes David Rokach (Senior Investment Manager at X Group Fund of Funds), and Anastasiia Kotaieva (beneficial owner of X Group stake), with X Group having multiple financing and conversion arrangements with the Company; these relationships are relevant to board independence oversight although no specific related-party transactions are attributed to Yeganeh .
  • CEO-related party exposure: Significant agreements with Star 26 (controlled by CEO Menachem Shalom) requiring board and stockholder approval; potential conflict management falls under Audit/Nominating oversight where Yeganeh is a member/chair .

Expertise & Qualifications

  • Financial services and derivatives trading experience; fund management background .
  • Audit Committee Financial Expert designation by the Board .
  • Education: BA in Economics & Administration (Ruppin College, 2004); ISA portfolio management license (2006) .

Equity Ownership

HolderShares Beneficially Owned% of Common Stock
Reuven Yeganeh (Director)10,000 <1%

Notes:

  • Vested vs unvested, options, and pledged shares: No director-specific breakdown or pledging disclosures for Yeganeh in the proxy .

Governance Assessment

  • Positives

    • Independent director with strong finance background; designated Audit Committee Financial Expert and serving as Audit Committee Chair, which bolsters internal control and audit oversight .
    • Clear committee engagement; Audit met three times; Compensation and Nominating met once, indicating functioning governance processes .
    • Shareholder support: Received 5.04M votes “FOR” at the 2025 Annual Meeting, suggesting investor confidence in board composition .
    • Company adopted a clawback policy in compliance with Nasdaq Rule 5608 on April 8, 2025, strengthening pay-for-performance accountability (primarily for executives) .
  • Watch items / RED FLAGS

    • Related-party ecosystem: Extensive transactions with entities connected to executives (e.g., Star 26 controlled by CEO; financing and conversions involving X Group where other directors have affiliations). While no Item 404 transactions involve Yeganeh directly, Audit and Nominating oversight (including Yeganeh) must actively manage these conflicts .
    • Concentrated shareholder influence: A director (Kotaieva) controls a 13.6% stake via X Group Fund of Funds LP, increasing potential for interlocks and influence dynamics that the Audit/Nominating committees should monitor .
    • Limited disclosure on director-specific performance metrics, vesting details, and attendance rates may constrain assessment of pay-for-performance and individual engagement beyond committee meeting counts .

Overall, Yeganeh’s financial expertise and independence in Audit leadership are positive governance signals, but the board’s related-party environment requires robust, transparent oversight—an area where his Audit Committee chair role is central .